Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976362 · ClinicalTrials.gov registry record · Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
A Phase 3 study of Carcinoma, Squamous Cell, Non-small-cell Lung, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
- 20
- Study locations
NCT03976362 is a Phase 3 study of Carcinoma, Squamous Cell, Non-small-cell Lung that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 851 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT03976362, a Phase 3 study of Carcinoma, Squamous Cell, Non-small-cell Lung, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to overall survival (OS). As of Amendment 07, there will be no further analyses for OS and patient-reported outcome assessments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Olaparib
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
Study Locations (20)
Florida
- Boca Raton Regional Hospital ( Site 0018) - Boca Raton
- Mid-Florida Cancer Centers ( Site 0022) - Orange City
- H. Lee Moffitt Cancer Center and Research Institute ( Site 0024) - Tampa
Illinois
- Mount Sinai Hospital Medical Center ( Site 0035) - Chicago
- Oncology of Northshore ( Site 0036) - Rolling Meadows
Montana
- Frontier Oncology ( Site 0052) - Billings
- Bozeman Health Deaconness Cancer Center ( Site 0053) - Bozeman
Buenos Aires
- Hospital Italiano Regional del Sur ( Site 0509) - Bahía Blanca
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0516) - Mar del Plata
Alabama
- Alabama Oncology Bruno Cancer Center ( Site 0001) - Birmingham
California
- Disney Family Cancer Center ( Site 0005) - Burbank
Georgia
- Columbus Regional Research Institute ( Site 0099) - Columbus
Indiana
- Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0039) - Merrillville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03976362
The ClinicalTrials.gov registry entry for NCT03976362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 851 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Squamous Cell, Non-small-cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03976362 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Illinois, Montana.
Frequently Asked Questions
What is clinical trial NCT03976362 about?
NCT03976362 is a clinical study titled "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)". The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance o...
What is the current status of trial NCT03976362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2019-06-28. Estimated completion is 2026-01-30.
What conditions does trial NCT03976362 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Non-small-cell Lung.
What interventions are being tested in trial NCT03976362?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Olaparib (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03976362?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03976362 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.